

January 2011

**ANNUAL DECLARATION OF INTERESTS
GLOBAL INITIATIVE FOR ASTHMA: BOARD OF DIRECTORS
1 January – 31 December 2010**

GINA Committee members disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

1. **Personal Benefits** refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings.
2. **Shares** refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/dependent children < 18 yrs). The company is to be listed, not the number of shares.
3. **Non-Personal Interests** refers to fees or grants paid to a GINA Committee member (or the Department/Institution on behalf of a GINA member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$1,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each member of the GINA Board of Directors for the year 2010 is presented in an effort to be as transparent as possible. For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Asthma (GINA)” on the website at: <<http://www.ginasthma.org>>.

SUMMARY FOR YEAR 2010:

Eric Bateman, Capetown, South Africa: *Personal Benefits* <\$10,000: Actelion, ALKAbello, Ammirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Elevation Pharma, Forest, GlaxoSmithKline, Hoffman LaRoche, Merck Sharp & Dohme, Novartis, Nycomed, Pfizer. *Shares:* none. *Non-Personal Interests:* none.

Louis-Philippe Boulet, Quebec City, Quebec Canada: *Personal Benefits* <\$10,000: AstraZeneca, GlaxoSmithKline. *Shares:* none. *Non-Personal Interests* <\$10,000: AstraZeneca, GlaxoSmithKline, Merck, Novartis. *Non-Personal Interests* >\$10,000: AsthmaCure, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Merck, Pharmaxis.

Alvaro Cruz, Salvador, Brazil: *Personal Benefits* <\$10,000: Chiesi, GlaxoSmithKline, Libbs, Merck Sharp & Dohme, Novartis. *Shares:* none. *Non-Personal Interests* >\$10,000: ACHE, Chiesi, Eurofarma, Mantecorp, Novartis.

Mark FitzGerald, Vancouver, British Columbia, Canada: *Personal Benefits* <\$10,000: Boehringer-Ingelheim, Novartis, Nycomed. *Personal Benefits* >\$10,000: AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme. *Shares:* none. *Non-Personal Interests* >\$10,000: Boehringer Ingelheim, Canadian Institute for Health Research, Genentech, GlaxoSmithKline, Medimmune, Novartis, Pharmaxis, Topigen, Wyeth.

Tari Haahtela, Helsinki Finland: *Personal Benefits <\$10,000:* Abdi Ibrahim, ALK, Leiras, Orion Pharma, Merck Sharp & Dohme. *Shares:* none. *Non-Personal Interests:* none.

Mark Levy, London, England, UK: *Personal Benefits <\$10,000:* ARIA, Chiesi, GlaxoSmithKline, MEDA, National Services for Health Improvement, Novartis, Respiroics, TEVA Pharmaceuticals. *Shares:* none. *Non-Personal Interests <\$10,000:* none.

Paul O'Byrne, Hamilton, Ontario, Canada: *Personal Benefits <\$10,000:* Abbott, Asmacure, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Wyeth. *Personal Benefits >\$10,000:* AstraZeneca. *Shares:* none. *Non-Personal Interests >\$10,000:* Asmacure, Acetelion, AstraZeneca, Genentech, Wyeth.

Ken Ohta, Tokyo, Japan: *Personal Benefits <\$10,000:* AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, IE Kyorin, Merck Sharp & Dohme, Novartis. *Shares:* none. *Non-Personal Interests:* none.

Pierluigi Paggiaro, Pisa, Italy: *Personal Benefits <\$10,000:* AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarium, Novartis, Nycomed, Valeas. *Shares:* none. *Non-Personal Interests <\$10,000:* GlaxoSmithKline, Menarium, Nycomed. *Non-Personal Interests >\$10,000:* AstraZeneca, Boehringer Ingelheim, Chiesi, Merck Sharp & Dohme, Novartis.

Soren Pedersen, Kolding, Denmark: *Personal Benefits <\$10,000:* GlaxoSmithKline, Nycomed. *Shares:* none. *Non-Personal Interests <\$10,000:* AstraZeneca.

Manuel Soto-Quiroz, San Jose, Costa Rica: *Personal Benefits <\$10,000:* AstraZeneca, Biostansi, GlaxoSmithKline, Merck Sharp & Dohme. *Shares:* none. *Non-Personal Interests:* none.

Gary Wong, Hong Kong: *Personal Benefits <\$10,000:* AstraZeneca, Nestle, Nycomed, Pfizer. *Personal Benefits >\$10,000:* GlaxoSmithKline, Merck Sharp & Dohme. *Shares:* none. *Non-Personal Interests:* none.